Traditional Chinese medicine compound liposome for rheumatic diseases and preparation method of traditional Chinese medicine compound liposome

By encapsulating Chinese medicine extracts in the bilayer structure of phospholipids, forming Chinese medicine compound liposomes, solving the problem of side effects of long-term use of existing drugs, achieving effective treatment of rheumatic diseases and reducing adverse reactions, providing a New treatment options.

CN118903016AInactive Publication Date: 2024-11-08新智杰(苏州)生物科技有限公司
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411322220.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Although existing drugs used for rheumatic diseases can relieve symptoms, long-term use may bring side effects, such as gastrointestinal bleeding and liver and kidney damage.

Method used

The phospholipid bilayer structure is used to encapsulate traditional Chinese medicine extracts, including the preparation of aconite, cinnamon twig, licorice, Anaestheticum, White Peony, Viagra, Chicken Blood Vine, Atractylodes, Papaya, and Extension Grass, etc., by improving the drug delivery system, Formation of Chinese medicine compound liposomes.

Benefits of technology

It improves the therapeutic effect of Chinese medicine compound prescriptions, reduces adverse drug reactions, and provides a new treatment option for rheumatic diseases, with good biocompatibility and efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903016A_ABST
    Figure CN118903016A_ABST
Patent Text Reader

Abstract

The invention provides a traditional Chinese medicine compound liposome for rheumatic diseases and a preparation method thereof, the traditional Chinese medicine compound liposome comprises a phospholipid bilayer structure and a traditional Chinese medicine extract, and the traditional Chinese medicine extract is encapsulated in the phospholipid bilayer structure; the traditional Chinese medicine extract is prepared from one or more of radix aconiti lateralis preparata, cassia twig, liquorice, rhizoma anemarrhenae, radix paeoniae alba, radix clematidis, caulis spatholobi, rhizoma atractylodis macrocephalae, pawpaw and lycopodium clavatum. The raw materials of the phospholipid bilayer structure comprise one or more of phospholipid (such as lecithin), cholesterol and Tween-80. According to the traditional Chinese medicine compound liposome for rheumatic diseases and the preparation method thereof provided by the invention, the traditional Chinese medicine compound liposome has good biocompatibility and efficacy, and can effectively relieve the symptoms of rheumatoid arthritis and gouty arthritis. According to the liposome preparation, by improving a drug delivery system, the treatment effect of a traditional Chinese medicine compound can be improved, the adverse reaction of drugs is reduced, and a new choice is provided for treatment of rheumatic diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of Chinese medicine preparations, and specifically relates to a Chinese medicine compound liposome for rheumatic diseases and a preparation method thereof; more specifically, to a Chinese medicine compound liposome for treating rheumatoid arthritis and gouty arthritis and a preparation method thereof. Background Art

[0002] Rheumatoid arthritis (RA) and gouty arthritis (GA) are two common rheumatic diseases, both of which are characterized by joint pain, swelling and dysfunction as the main clinical manifestations. Current treatment options are mostly nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids and disease-modifying antirheumatic drugs (DMARDs). Although these drugs can relieve symptoms, long-term use may cause side effects, such as gastrointestinal bleeding, liver and kidney damage, etc. Summary of the invention

[0003] The purpose of the present invention is to provide a Chinese medicine compound liposome for rheumatic diseases and a preparation method thereof, aiming to solve the technical problem that the existing drugs in the prior art can relieve symptoms but may cause side effects when used for a long time.

[0004] To achieve the above purpose, the technical solution adopted by the present invention is: to provide a Chinese medicine compound liposome for rheumatic diseases and a preparation method thereof, comprising: a phospholipid bilayer structure and a Chinese medicine extract, wherein the Chinese medicine extract is encapsulated in the phospholipid bilayer structure; the raw materials used in the Chinese medicine extract include one or more of prepared aconite root, cassia twig, liquorice, rhizoma anemarrhenae, white peony root, radix clematis, spatholobi, atractylodes macrocephala, papaya, and herba lycopodii. The raw materials of the phospholipid bilayer structure include one or more of phospholipids (such as lecithin), cholesterol, and Tween-80.

[0005] Preferably, the Chinese medicine extract comprises the following raw materials in parts by weight: 5-25 parts of processed aconite root, 3-10 parts of cinnamon twig, 7-20 parts of liquorice, 5-25 parts of anemarrhena asphodeloides, 5-35 parts of white peony root, 6-25 parts of clematis root, 15-30 parts of millettia reticulata, 10-45 parts of atractylodes macrocephala, 5-25 parts of papaya, and 6-30 parts of lycopodii herba.

[0006] Preferably, the phospholipid bilayer structure is composed of the following raw materials in parts by weight: 20-80 parts of phospholipids, 5-13 parts of cholesterol, and 0-6 parts of Tween-80.

[0007] A method for preparing a Chinese medicine compound liposome for treating rheumatoid arthritis and gouty arthritis, characterized in that the method is used to prepare a Chinese medicine compound liposome for treating rheumatoid arthritis and gouty arthritis as described in any one of the above, comprising the following steps:

[0008] Preparation of Chinese herbal medicine extracts;

[0009] The liposome product is prepared by encapsulating the Chinese herbal medicine extract in a phospholipid bilayer structure.

[0010] Preferably, the preparation of the Chinese herbal extract comprises:

[0011] Weigh the raw materials required for preparing the Chinese medicine extract according to a preset ratio, and grind the raw materials to a size of 60-80 meshes;

[0012] Divide the crushed Chinese medicinal materials into several portions according to the proportion (according to the capacity of the extraction equipment and the convenience of operation), and then soak them with cold boiled water or purified water;

[0013] The extract liquid is obtained by decoction;

[0014] The extract is filtered and concentrated to obtain the concentrated solution which is the Chinese herbal medicine extract.

[0015] Preferably, the preparation of the liposome product by encapsulating the Chinese medicine extract in a phospholipid bilayer structure comprises:

[0016] Weigh lecithin, cholesterol, Tween-80 and anhydrous ethanol respectively according to a preset ratio, and dissolve lecithin, cholesterol and Tween-80 in anhydrous ethanol to form an organic phase;

[0017] Weigh the Chinese herbal medicine extract, add it to phosphate buffer, preheat it and form a uniform aqueous phase by magnetic stirring;

[0018] The ethanol in the organic phase was removed to allow the organic lipids to form a uniform film at the bottom of the flask.

[0019] The preheated aqueous phase is added into the flask with the film, stirred for hydration for 0.5-1.5 hours, and then ultrasonicated for 5-30 minutes to obtain the traditional Chinese medicine compound liposome.

[0020] Preferably, the method comprises weighing lecithin, cholesterol, Tween-80 and anhydrous ethanol respectively according to a preset ratio, and dissolving lecithin, cholesterol and Tween-80 in anhydrous ethanol to form an organic phase, and further comprising:

[0021] An appropriate amount of concentrated solution of the Chinese herbal medicine extract is added to the organic phase and mixed thoroughly to ensure that the active ingredients are evenly distributed in the organic phase.

[0022] Preferably, the step of obtaining the extraction liquid by decoction comprises:

[0023] The first extract is obtained by decoction;

[0024] Add 7 times the volume of water to the residue after the first extraction, heat to boiling again, and simmer over medium-low heat for 60 minutes; filter the liquid to obtain the second extract;

[0025] Add 5 times the volume of water to the residue after the second extraction and boil for 60 minutes. Filter the liquid to obtain the third extract;

[0026] Combine the extracted solutions and mix them evenly.

[0027] Preferably, the extract is filtered and concentrated to obtain a concentrated solution, i.e., a Chinese medicine extract, comprising:

[0028] Dilute the concentrate to the desired concentration according to the needs of liposome preparation

[0029] Preferably, the mass ratio of cholesterol to lecithin is 1:4.

[0030] The beneficial effects of the Chinese medicine compound liposome for rheumatic diseases and the preparation method thereof provided by the present invention are as follows: compared with the prior art, the Chinese medicine compound liposome for rheumatic diseases and the preparation method thereof provided by the present invention have good biocompatibility and drug efficacy, and can effectively alleviate the symptoms of rheumatoid arthritis and gouty arthritis. The liposome preparation can improve the therapeutic effect of the Chinese medicine compound and reduce the adverse reactions of the drug by improving the drug delivery system, thus providing a new option for the treatment of rheumatic diseases. The Chinese medicine compound liposome of the present invention is suitable for the adjuvant treatment of rheumatoid arthritis and gouty arthritis, and can also be used for the research and application of other rheumatic diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0032] Figure 1 The therapeutic effect of traditional Chinese medicine compound liposome on rat gouty arthritis (GA) model is shown. (A) Joint diameter of rat GA model, (B) Arthritis score of rat GA model.

[0033] Figure 2 The therapeutic effect of Chinese herbal compound liposomes on rat rheumatoid arthritis (RA) model is shown. (A) Joint diameter of rat RA model, (B) Arthritis score of rat RA model;

[0034] Figure 3The physical structure diagram of a traditional Chinese medicine compound liposome for rheumatic diseases provided by the present invention is shown. DETAILED DESCRIPTION

[0035] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0036] Please also read Figures 1 to 3 , now a Chinese medicine compound liposome for rheumatic diseases provided by the present invention is described. The Chinese medicine compound liposome for rheumatic diseases and its preparation method include: a phospholipid bilayer structure and a Chinese medicine extract, wherein the Chinese medicine extract is encapsulated in the phospholipid bilayer structure; the raw materials used in the Chinese medicine extract include one or more of prepared aconite root, cassia twig, liquorice, rhizoma anemarrhenae, white peony root, clematis root, millettia reticulata, atractylodes macrocephala, papaya, and lycopodiella cuneata. The raw materials of the phospholipid bilayer structure include one or more of phospholipids (such as lecithin), cholesterol, and Tween-80.

[0037] In some embodiments, the Chinese herbal medicine extract includes a water-soluble Chinese herbal medicine extract and a fat-soluble Chinese herbal medicine extract, wherein the fat-soluble Chinese herbal medicine extract is encapsulated on the phospholipid bilayer structure, and the water-soluble Chinese herbal medicine extract is encapsulated in the phospholipid bilayer structure.

[0038] In some embodiments of any embodiment described herein, the raw materials used in the Chinese medicine extract include Radix Aconiti Lateralis Preparata, Cinnamomum cassia, Glycyrrhiza uralensis, Rhizoma Anemarrhenae, Radix Paeoniae Alba, Radix Clematis, Caulis Spatholobi, Rhizoma Atractylodis Macrocephalae, Chaenomeles sinensis, and Herba Lycopodii. The raw materials of the phospholipid bilayer structure include phospholipids (such as lecithin), cholesterol, and Tween-80.

[0039] In some embodiments, the raw materials used in the Chinese medicine extract are processed aconite, cinnamon twig, liquorice, rhizoma anemarrhenae, white peony root, radix clematis, spatholobi, atractylodes macrocephala, papaya, and herba lycopodii. Preferably, the Chinese medicine extract is composed of the following raw materials in parts by weight: 5-25 parts of processed aconite, 3-10 parts of cinnamon twig, 7-20 parts of liquorice, 5-25 parts of rhizoma anemarrhenae, 5-35 parts of white peony root, 6-25 parts of radix clematis, 15-30 parts of spatholobi, 10-45 parts of atractylodes macrocephala, 5-25 parts of papaya, and 6-30 parts of herba lycopodii.

[0040] In some embodiments, the raw materials of the phospholipid bilayer structure include phospholipids (such as lecithin), cholesterol and Tween-80. Preferably, the phospholipid bilayer structure is composed of the following raw materials in mass fractions: 20-80 parts of phospholipids, 5-13 parts of cholesterol, and 0-6 parts of Tween-80.

[0041] Please also read Figures 1 to 3The present invention also provides a method for preparing a Chinese medicine compound liposome for rheumatic diseases, comprising the following steps:

[0042] S1. preparing Chinese herbal medicine extracts;

[0043] The implementation of this step includes:

[0044] S1.1, weigh the raw materials required for preparing the Chinese medicine extract according to the preset ratio, mix the raw materials, and then grind them into 60-80 mesh. Specifically, the Chinese medicine extract is composed of the following raw materials in parts by weight: 5-25 parts of processed aconite, 3-10-5 parts of cinnamon twig, 7-20 parts of liquorice, 5-25 parts of anemarrhena, 5-35 parts of white peony root, 6-25 parts of clematis, 15-30 parts of millettia reticulata, 10-45 parts of atractylodes macrocephala, 5-25 parts of papaya, and 6-30 parts of lycopodiella ciliata.

[0045] S1.2, soak the raw materials. Specifically, the crushed Chinese medicinal materials are divided into several portions according to the experimental grouping (according to the capacity of the extraction equipment and the convenience of operation), and then soaked in pure water. The soaking time is greater than 20 minutes (such as 25 minutes, 30 minutes, 40 minutes, 60 minutes) to fully absorb water and soften the medicinal materials;

[0046] S1.3. Obtain the extraction liquid by decoction.

[0047] The first extract is obtained by decoction. Specifically, the soaked medicinal materials are placed in a decoction pot, and water 10 times the weight of the medicinal materials is added (for example, if the total weight of the medicinal materials is 100g, then 1000g of water is added). Heat to boiling and maintain medium-low heat for 60 minutes. During the decoction process, keep the pot lid half-covered to prevent excessive evaporation of water. After the decoction is completed, filter the medicinal liquid to obtain the first extract;

[0048] The second extraction is performed. Specifically, the medicinal residue after the first extraction is added with 5-15 times the volume of clean water, heated to boiling again, and decocted on medium-low heat for 20-60 minutes. The medicinal liquid is filtered to obtain the second extract.

[0049] The third extraction is performed. Specifically, the residue after the second extraction is added with 5-15 times the volume of clean water, and boiled for 20-60 minutes. The liquid medicine is filtered to obtain the third extract.

[0050] Combine the extracted liquids. Combine the extracted liquids and mix them evenly.

[0051] S1.4. Filter and concentrate the extract to obtain the concentrated solution which is the Chinese herbal medicine extract.

[0052] The mixed extract is coarsely filtered to remove undissolved particles and impurities. The extract is concentrated to a concentration of more than 80% using a rotary evaporator. The temperature should be kept below 60°C during the rotary evaporation process to prevent the effective ingredients in the medicinal materials from being damaged. The concentrated extract is the Chinese medicine extract and is stored in a sealed container for further use.

[0053] This step also includes: diluting the concentrated solution to a desired concentration according to the requirements of liposome preparation (for example, adjusting according to the target liposome loading amount).

[0054] S2. Prepare liposome products by encapsulating Chinese medicine extracts in a phospholipid bilayer structure.

[0055] The implementation of this step includes:

[0056] S2.1, Preparation of organic phase: Lecithin, cholesterol, Tween-80 and anhydrous ethanol are weighed respectively according to the preset ratio, and lecithin, cholesterol and Tween-80 are added in sequence and dissolved in anhydrous ethanol to form an organic phase.

[0057] An appropriate amount of concentrated solution of the Chinese herbal medicine extract is added to the organic phase and mixed thoroughly to ensure that the Chinese herbal medicine extract is evenly distributed in the organic phase.

[0058] S2.2, aqueous phase preparation: Weigh the Chinese herbal medicine extract, add it to phosphate buffer, preheat it and form a uniform aqueous phase by magnetic stirring.

[0059] S2.3. Obtaining Chinese medicine compound liposomes.

[0060] The ethanol in the organic phase was removed to allow the organic lipids to form a uniform film at the bottom of the flask.

[0061] The preheated aqueous phase was added to the flask containing the film, stirred for hydration for 0.5-1.5 hours, 1 hour, and then ultrasonicated for 5-30 minutes; 12 minutes to obtain the traditional Chinese medicine compound liposomes.

[0062] Example 1 Preparation of Chinese medicine compound liposomes

[0063] A method for preparing a Chinese medicine compound liposome for treating rheumatoid arthritis and gouty arthritis comprises the following steps:

[0064] S1. preparing Chinese herbal medicine extracts;

[0065] The implementation of this step includes:

[0066] S1.1, weigh the raw materials required for preparing the Chinese medicine extract according to the preset ratio, and crush the raw materials to a mesh size of 60-80. Specifically, the Chinese medicine extract is composed of the following raw materials by weight: 5-25 parts of processed aconite, 3-10 parts of cassia twig, 7-20 parts of licorice, 5-25 parts of rhizoma anemarrhenae, 5-35 parts of white peony root, 6-25 parts of clematis, 15-30 parts of millettia reticulata, 10-45 parts of atractylodes macrocephala, 5-25 parts of papaya, and 6-30 parts of lycopodiella ciliata.

[0067] S1.2, soak the raw materials. Specifically, the crushed Chinese medicinal materials are divided into several portions according to the proportion (according to the capacity of the extraction equipment and the convenience of operation), and then soaked in cold boiled water or purified water. The soaking time is 30 minutes to fully absorb water and soften the medicinal materials;

[0068] S1.3. Obtain the extraction liquid by decoction.

[0069] The first extract is obtained by decoction. Specifically, the soaked medicinal materials are placed in a decoction pot, and 10 times the weight of clean water is added (for example, if the total weight of the medicinal materials is 100g, then 1000g of clean water is added). Heat to boiling and maintain medium-low heat for 60 minutes. During the decoction process, keep the pot lid half-covered to prevent excessive evaporation of water. After the decoction is completed, filter the medicinal liquid to obtain the first extract;

[0070] The second extraction was performed. Specifically, the residue after the first extraction was added with 7 times the weight of clean water, heated to boiling again, and decocted on medium-low heat for 60 minutes. The liquid medicine was filtered to obtain the second extract.

[0071] The third extraction is performed. Specifically, the residue after the second extraction is added with 5 times the weight of clean water, and boiled for 60 minutes. The liquid medicine is filtered to obtain the third extract.

[0072] Combine the extracted liquids. Combine the extracted liquids and mix them evenly.

[0073] S1.4. Filter and concentrate the extract to obtain the concentrated solution which is the Chinese herbal medicine extract.

[0074] The mixed extract is coarsely filtered to remove undissolved particles and impurities. The extract is concentrated to the desired concentration using a rotary evaporator. The temperature should be kept below 60°C during the rotary evaporation process to prevent the active ingredients in the medicinal materials from being damaged. The concentrated extract is the Chinese herbal medicine extract and is stored in a sealed container for further use.

[0075] This step also includes: diluting the concentrated solution to a desired concentration according to the requirements of liposome preparation (for example, adjusting according to the target liposome loading amount), and specifically, diluting the concentrated solution to a desired concentration of 80%.

[0076] S2. Prepare liposome products by encapsulating Chinese medicine extracts in a phospholipid bilayer structure.

[0077] The implementation of this step includes:

[0078] S2.1. Preparation of organic phase: Lecithin, cholesterol and Tween-80 are weighed according to a preset ratio and dissolved in anhydrous ethanol to form an organic phase.

[0079] Weigh 50 mg of lecithin, 8 mg of cholesterol and 10 μL of Tween-80, and dissolve them in 3 mL of anhydrous ethanol to form an organic phase.

[0080] An appropriate amount of concentrated solution of the Chinese herbal medicine extract is added to the organic phase and mixed thoroughly to ensure that the Chinese herbal medicine extract is evenly distributed in the organic phase.

[0081] S2.2, aqueous phase preparation: Weigh 10 mL of the concentrated Chinese herbal extract, add 20 mL of 0.01 mol / L phosphate buffer, preheat at 50°C and form a uniform aqueous phase by magnetic stirring.

[0082] S2.3. Obtaining Chinese medicine compound liposomes.

[0083] The ethanol in the organic phase was removed to allow the organic lipids to form a uniform film at the bottom of the flask.

[0084] The preheated aqueous phase was added into the flask containing the film, stirred for hydration for 1 hour, and then ultrasonicated for 12 minutes to obtain the traditional Chinese medicine compound liposomes.

[0085] Experimental data analysis

[0086] Characterization of the properties of Chinese herbal compound liposomes: Determination of the average particle size, polydispersity index and Zeta potential of different liposomes: The composite functional liposomes were diluted to an appropriate concentration with distilled water, and appropriate amounts of samples were placed in a polystyrene cell and a potential cell for equilibration for 120 seconds. The average particle size, polydispersity index (PDI) and Zeta potential were determined using a Malvern laser nanoparticle size analyzer, and the data were processed using dynamic light scattering processing software.

[0087] Determination of the encapsulation efficiency of Chinese medicine compound liposomes: The encapsulation efficiency of the composite functional liposomes was determined by ultrafiltration centrifugation. Use a pipette to transfer 2 mL of the composite functional liposome suspension, place it in the top sleeve of a Millipore ultrafiltration centrifuge tube (with a molecular weight cutoff of 100 kDa), and centrifuge at 7000 r / min for 15 minutes. Remove the top sleeve, aspirate the liquid in the tube, and calculate the mass of the free composite functional liposomes according to the method in 1.3.2. Repeat the experiment 3 times and take the average value. Calculate the encapsulation efficiency.

[0088] Determination of storage stability of Chinese medicine compound liposomes: The composite functional liposomes were stored in the dark at 4 and 25°C, and samples were taken at 0, 1, 3, 5, and 7 days to analyze the average particle size, PDI, and encapsulation efficiency of the composite functional liposomes.

[0089] 1. Preparation of Chinese medicine compound liposomes by thin film hydration method and physical property testing Different liposomes were prepared by thin film hydration method, and the average particle size, PDI, Zeta potential and encapsulation efficiency of different liposomes were tested. The experimental results of the product prepared in Example 1 are shown in Table 1.

[0090] Table 1 Physical properties of Chinese medicine compound liposomes

[0091] Particle size / nm PDI Zeta point / mV Encapsulation rate% 101.4±3.29 0.221±0.04 -36.6±0.26 83.1±2.14

[0092] The experiment tested the physical properties of the Chinese medicine compound liposomes, including particle size, PDI, Zeta potential and encapsulation efficiency. The results showed that the average particle size of these liposomes was about 101.4nm, and the PDI was less than 0.3, indicating that the particle size distribution was uniform. The Zeta potential was negative, indicating that the liposomes were negatively charged and had stable dispersion. The encapsulation efficiency exceeded 80%, among which the encapsulation efficiency of the hair care black hair liposome was the highest, reaching 85.3%. In general, the liposomes prepared by the thin film hydration method showed good stability and high encapsulation efficiency.

[0093] 2. Results of optimization of preparation conditions of Chinese medicine compound liposomes.

[0094] Table 1 Effect of preparation conditions on average particle size and encapsulation efficiency of Chinese medicine compound liposomes

[0095]

[0096]

[0097] It should be noted that the mass (mg) of lecithin is 20.0. This means that the specific steps in step S2.1, preparation of the organic phase are: weigh 20 mg of lecithin, 8 mg of cholesterol and 10 μL of Tween-80, dissolve in 3 mL of anhydrous ethanol to form an organic phase. The remaining steps are the same as in Example 1.

[0098] The weight of lecithin (mg) is 40.0. The meaning is that the specific steps in step S2.1, preparation of the organic phase are: weigh 40 mg of lecithin, 8 mg of cholesterol and 10 μL of Tween-80, dissolve in 3 mL of anhydrous ethanol to form an organic phase. The remaining steps are the same as in Example 1.

[0099] m(cholesterol):m(phosphatidylcholine) 1:2. The meaning is that the specific steps in step S2.1, preparation of organic phase are: weigh 20 mg phosphatidylcholine, 10 mg cholesterol and 10 μL Tween-80, dissolve in 3 mL anhydrous ethanol to form an organic phase. The remaining steps are the same as in Example 1.

[0100] m(cholesterol):m(phosphatidylcholine) 1:3. The meaning is that the specific steps in step S2.1, preparation of organic phase are: weigh 30 mg phosphatidylcholine, 10 mg cholesterol and 10 μL Tween-80, dissolve in 3 mL anhydrous ethanol to form an organic phase. The remaining steps are the same as in Example 1.

[0101] m(cholesterol):m(lecithin)1:4. The meaning is that the specific steps in step S2.1, preparation of organic phase are: weigh 40 mg lecithin, 10 mg cholesterol and 10 μL Tween-80, dissolve in 3 mL anhydrous ethanol to form an organic phase. The remaining steps are the same as in Example 1.

[0102] m(traditional Chinese medicine extract):m(lecithin) 1:2 means that the specific steps in step S2.1, preparation of the organic phase are: weigh 60 mg of lecithin, 12 mg of cholesterol and 10 μL of Tween-80, dissolve them in 3 mL of anhydrous ethanol to form an organic phase.

[0103] Take 30 mg of the concentrated solution of the Chinese herbal medicine extract and add it to the organic phase, and mix thoroughly to make the active ingredients evenly distributed in the organic phase.

[0104] S2.2, aqueous phase preparation: Weigh 30 mg of the concentrated Chinese herbal extract, add 20 mL of 0.01 mol / L phosphate buffer, preheat at 50°C and form a uniform aqueous phase by magnetic stirring.

[0105] m(traditional Chinese medicine extract):m(lecithin)1:3 means,

[0106] The specific steps in step S2.1, preparation of the organic phase are as follows: 60 mg of lecithin, 12 mg of cholesterol and 10 μL of Tween-80 are weighed and dissolved in 3 mL of anhydrous ethanol to form an organic phase.

[0107] Take 20 mg of the concentrated solution of the Chinese herbal medicine extract and add it to the organic phase, and mix thoroughly to make the active ingredients evenly distributed in the organic phase.

[0108] S2.2, aqueous phase preparation: Weigh 20 mg of the concentrated Chinese herbal extract, add 20 mL of 0.01 mol / L phosphate buffer, preheat at 50°C and form a uniform aqueous phase by magnetic stirring.

[0109] Different lecithin mass, cholesterol to lecithin mass ratio, and Chinese medicine extract to lecithin mass ratio had a significant effect on the encapsulation efficiency of Chinese medicine compound liposomes. When the lecithin mass was 60 mg and the cholesterol to lecithin mass ratio was 1:4, the liposome encapsulation efficiency was the highest, which was 86.22% and 82.22%, respectively. When the mass ratio of decarboxylated carnosine to lecithin was 1:4, the encapsulation efficiency reached 80.22%.

[0110] Example 2

[0111] A method for preparing a Chinese medicine compound liposome for treating rheumatoid arthritis and gouty arthritis comprises the following steps:

[0112] S1. Prepare a Chinese herbal medicine extract; the specific preparation steps are the same as step S1 in Example 1.

[0113] S2. Prepare liposome products by encapsulating Chinese medicine extracts in a phospholipid bilayer structure.

[0114] The implementation of this step includes:

[0115] S2.1. Preparation of organic phase.

[0116] Weigh 60 mg of lecithin, 12 mg of cholesterol and 10 uL of Tween-80, and dissolve them in 3 mL of anhydrous ethanol to form an organic phase.

[0117] An appropriate amount of concentrated solution of 12 mg of the Chinese herbal medicine extract was added to the organic phase and mixed thoroughly to ensure that the active ingredients were evenly distributed in the organic phase.

[0118] S2.2, aqueous phase preparation: Weigh 12 mg of the concentrated Chinese herbal extract, add 20 mL of 0.01 mol / L phosphate buffer, preheat at 50°C and form a uniform aqueous phase by magnetic stirring.

[0119] S2.3. Obtaining Chinese medicine compound liposomes.

[0120] The ethanol in the organic phase was removed to allow the organic lipids to form a uniform film at the bottom of the flask.

[0121] The preheated aqueous phase was added into the flask containing the film, stirred for hydration for 1 hour, and then ultrasonicated for 12 minutes to obtain the traditional Chinese medicine compound liposomes.

[0122] The encapsulation efficiency of the Chinese medicine compound liposome prepared in Example 2 was significantly improved.

[0123] Under optimized preparation conditions, the encapsulation rate of Chinese medicine compound liposomes can be significantly improved.

[0124] 3. Analysis of storage stability of Chinese medicine compound liposomes

[0125] Liposome preparations are easily affected by the environment during daily processing, transportation and storage, resulting in aggregation, precipitation and other phenomena, which lead to leakage of embedded substances and changes in particle size distribution. The composite functional liposomes prepared under optimized conditions (i.e., the product obtained in Example 2) were divided into two parts, respectively placed at 4 and 25 ° C in the dark for a certain period of time, and the changes in the particle size distribution and encapsulation rate of the composite functional liposomes under different storage conditions were regularly detected to determine the most suitable storage conditions for the samples. The storage stability experiment is shown in the table below. The particle size of the traditional Chinese medicine compound liposomes stored at 4 ° C did not change significantly. In comparison, the particle size of the composite functional liposomes stored at 25 ° C increased significantly; with the extension of storage time, the encapsulation rate of the composite functional liposomes stored at 25 ° C was significantly lower than that of the composite functional liposomes stored at 4 ° C. The relatively high stability of the traditional Chinese medicine compound liposomes at low temperature (compared with other storage conditions in the same study) can be attributed to the maintenance of Zeta potential in a low temperature environment, the reduction of bilayer fluidity, and the delay of the oxidation process of unsaturated fatty acids in the membrane material. Higher ambient temperature will change the lipid crystal structure, soften the lipid membrane and increase its fluidity, causing the embedded substances to leak out of the liposomes faster.

[0126] Table 3 Storage stability analysis of Chinese medicine compound liposomes

[0127]

[0128]

[0129] The above stability results show that the particle size and encapsulation efficiency of liposomes change to varying degrees at both 4°C and 25°C. Overall, liposomes stored at 4°C show higher stability in terms of particle size and encapsulation efficiency. After 7 days of storage, the particle size increases slightly and the encapsulation efficiency decreases slightly. However, the particle size of liposomes stored at 25°C increases significantly during storage, and the encapsulation efficiency decreases significantly. The results show that storage conditions at 4°C are more conducive to maintaining the stability of liposomes and extending their shelf life.

[0130] 4. Cytotoxicity of Chinese medicine compound liposomes (i.e., the product prepared in Example 2):

[0131] The cell viability of different concentrations of Chinese herbal compound liposomes was higher than 90%, indicating that the liposomes had low cytotoxicity within the concentration range used. At the highest concentration of 200 μg / mL, the cell viability was 95.6±4.0%, and no significant toxicity was observed.

[0132]

[0133] The present invention provides a Chinese medicine compound liposome for rheumatic diseases and a preparation method thereof, which has good biocompatibility and drug efficacy compared with the prior art, and can effectively relieve the symptoms of rheumatoid arthritis and gouty arthritis. The liposome preparation can improve the therapeutic effect of the Chinese medicine compound and reduce the adverse reactions of the drug by improving the drug delivery system, thereby providing a new option for the treatment of rheumatic diseases. The Chinese medicine compound liposome of the present invention is suitable for the adjuvant treatment of rheumatoid arthritis and gouty arthritis, and can also be used for the research and application of other rheumatic diseases. It can improve the therapeutic effect and reduce side effects.

[0134] Figure 1 The therapeutic effect of Chinese herbal compound liposomes on the rat gouty arthritis (GA) model was shown. The results showed that during the experiment, the joint diameter of the rats in the treatment group was significantly reduced, especially at different time points after the administration of Chinese herbal compound liposomes. Compared with the model control group, the joint swelling of the rats in the treatment group was significantly reduced, showing the potential efficacy of Chinese herbal compound liposomes in relieving gouty arthritis. At the same time, the synovitis score also showed a similar trend, and the inflammation score of the treatment group was significantly lower than that of the control group, indicating that Chinese herbal compound liposomes can effectively inhibit the occurrence and development of joint inflammation. These results show that Chinese herbal compound liposomes have a good therapeutic effect in improving joint inflammation and swelling, providing experimental support for its use in the treatment of gouty arthritis.

[0135] Figure 2 The therapeutic effect of Chinese herbal compound liposomes on the rat rheumatoid arthritis (RA) model was demonstrated. Compared with the control group, the joint diameter of rats treated with Chinese herbal compound liposomes was significantly reduced, indicating that the compound can effectively reduce joint swelling caused by rheumatoid arthritis. In addition, the synovitis score results also showed that the synovitis symptoms of rats in the treatment group were significantly improved, and the synovitis score was significantly lower than that in the model group. This further verifies the anti-inflammatory effect of Chinese herbal compound liposomes in rheumatoid arthritis, suggesting that it has potential therapeutic effects on controlling inflammation and alleviating symptoms. These data lay the foundation for the application of Chinese herbal compound liposomes in the treatment of RA.

[0136] Verification of the effect of Chinese medicine compound liposomes:

[0137] The cytotoxicity and efficacy of liposomes were evaluated by in vitro cell experiments (such as the MTT assay).

[0138] Cell culture: Human synovial cell line was selected as the model cell. The cells were cultured in DMEM medium containing 10% fetal bovine serum at 37°C and 5% CO. 2 The cells are cultured under the appropriate conditions and passaged or subjected to experimental treatment when the cells grow to 80%-90% confluence.

[0139] MTT experimental steps: Cell seeding: L929 cells were plated at 5×10 4 The cells were inoculated in a 96-well plate at a density of 100 cells and cultured for 24 hours to allow them to adhere to the wall. Drug treatment: Different concentrations of Chinese medicine compound liposomes (such as 0, 10, 25, 50, 100, 200 μg / mL) were prepared, and 3 replicate wells were set up for each group. A control group was also set up, and an equal volume of culture medium was added. MTT staining: After 24, 48, and 72 hours of treatment, 20 μL of 5 mg / mL MTT solution was added to each well and incubated for another 4 hours. Dissolution and determination: 150 μL DMSO was added to dissolve the purple formazan crystals formed and shaken for 10 minutes. The absorbance value was measured at 570 nm using an enzyme reader. Cell viability calculation: Cell viability (%) = (absorbance value of the experimental group / absorbance value of the control group) × 100.

[0140] Animal model pharmacodynamic evaluation

[0141] Animal Model:

[0142] Gouty arthritis (GA) model: 8-week-old male C57BL / 6 mice were selected and 0.1 mL of sodium urate (MSU) crystal suspension was injected into the joint cavity to induce acute inflammation of the right ankle joint to establish the GA model.

[0143] Rheumatoid arthritis (RA) model: 8-week-old male SD rats were selected and 0.1 mL of complete Freund's adjuvant (CFA) was injected subcutaneously to induce inflammation in the rat toe joints to establish the RA model.

[0144] Experimental groups: The animals were randomly divided into 6 groups, with 10 animals in each group, namely normal control group, model control group, low-dose group of Chinese medicine compound liposome (50 mg / kg), medium-dose group (100 mg / kg), high-dose group (200 mg / kg) and positive control group (methotrexate, MTX).

[0145] Administration: The Chinese medicine compound liposome was injected through the tail vein once a day for 28 consecutive days. The positive control group was given methotrexate (MTX) twice a week at a dose of 1 mg / kg.

[0146] Efficacy evaluation: Joint swelling measurement: Use a vernier caliper to measure the diameter of the metatarsophalangeal joint of the rat's hind foot and record the degree of inflammation. The data are expressed as the change in swelling before and after treatment. Arthritis score: Refer to the Arthritis score system to evaluate the improvement of joint function.

[0147] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A Chinese medicine compound liposome for rheumatic diseases, characterized in that: include: A phospholipid bilayer structure and a Chinese herbal medicine extract, wherein the Chinese herbal medicine extract is encapsulated in the phospholipid bilayer structure; The raw materials used in Chinese medicine extracts include one or more of Radix Aconiti Lateralis Preparata, Cinnamomum cassia, Glycyrrhiza uralensis, Rhizoma Anemarrhenae, Radix Paeoniae Alba, Radix Clematis, Caulis Spatholobi, Rhizoma Atractylodis Macrocephalae, Chaenomeles sinensis, and Herba Lycopodii. The raw materials of the phospholipid bilayer structure include one or more of phospholipids (such as lecithin), cholesterol, and Tween-80.

2. A Chinese medicinal compound liposome for rheumatic diseases as claimed in claim 1, characterized in that: The Chinese medicine extract comprises the following raw materials in parts by weight: 5-25 parts of processed aconite root, 3-10-5 parts of cassia twig, 7-20 parts of liquorice, 5-25 parts of rhizoma anemarrhenae, 5-35 parts of white peony root, 6-25 parts of clematis root, 15-30 parts of millettia reticulata, 10-45 parts of atractylodes macrocephala, 5-25 parts of papaya and 6-30 parts of lycopodiella ciliata.

3. The Chinese medicinal compound liposome for rheumatic diseases according to claim 1, characterized in that: The phospholipid bilayer structure is composed of the following raw materials in parts by mass: 20-80 parts of phospholipids, 5-13 parts of cholesterol, and 0-6 parts of Tween-80.

4. A method for preparing a Chinese medicine compound liposome for rheumatic diseases, characterized in that: The method for preparing a Chinese medicine compound liposome for rheumatic diseases as claimed in any one of claims 1 to 3 comprises the following steps: Preparation of Chinese herbal medicine extracts; The liposome product is prepared by encapsulating the Chinese herbal medicine extract in a phospholipid bilayer structure.

5. The method for preparing a Chinese medicine compound liposome for rheumatic diseases according to claim 4, characterized in that: The preparation of the Chinese medicine extract comprises: Weigh the raw materials required for preparing the Chinese medicine extract according to a preset ratio, and grind the raw materials to a size of 60-80 meshes; Divide the crushed Chinese medicinal materials into several portions according to the proportion (according to the capacity of the extraction equipment and the convenience of operation), and then soak them with cold boiled water or purified water; The extract liquid is obtained by decoction; The extract is filtered and concentrated to obtain a concentrated solution which is the Chinese herbal medicine extract.

6. The Chinese medicinal compound liposome for rheumatic diseases according to claim 5, characterized in that: The method of preparing the liposome product by encapsulating the Chinese medicine extract in a phospholipid bilayer structure comprises: Weigh lecithin, cholesterol, Tween-80 and anhydrous ethanol respectively according to a preset ratio, and dissolve lecithin, cholesterol and Tween-80 in anhydrous ethanol to form an organic phase; Weigh the Chinese herbal medicine extract, add it to phosphate buffer, preheat it and form a uniform aqueous phase by magnetic stirring; The ethanol in the organic phase was removed to allow the organic lipids to form a uniform film at the bottom of the flask. The preheated aqueous phase is added into the flask with the film, stirred for hydration for 0.5-1.5 hours, and then ultrasonicated for 5-30 minutes to obtain the traditional Chinese medicine compound liposome.

7. The method for preparing a Chinese medicine compound liposome for rheumatic diseases according to claim 6, characterized in that: The method further comprises: weighing lecithin, cholesterol, Tween-80 and anhydrous ethanol respectively according to a preset ratio, and dissolving lecithin, cholesterol and Tween-80 in anhydrous ethanol to form an organic phase; An appropriate amount of concentrated solution of the Chinese herbal medicine extract is added to the organic phase and mixed thoroughly to ensure that the active ingredients are evenly distributed in the organic phase.

8. The method for preparing a Chinese medicine compound liposome for rheumatic diseases according to claim 5, characterized in that: The extracting liquid obtained by decoction comprises: The first extract is obtained by decoction; Add 7 times the volume of water to the residue after the first extraction, heat to boiling again, and simmer over medium-low heat for 60 minutes; filter the liquid to obtain the second extract; Add 5 times the volume of water to the residue after the second extraction and boil for 60 minutes. Filter the liquid to obtain the third extract; Combine the extracted solutions and mix them evenly.

9. The method for preparing a Chinese medicine compound liposome for rheumatic diseases according to claim 5, characterized in that: The extract is filtered and concentrated to obtain a concentrated solution, which is a Chinese medicine extract comprising: According to the needs of liposome preparation, the concentrate is diluted to the desired concentration.

10. The method for preparing a Chinese medicine compound liposome for rheumatic diseases according to claim 6, characterized in that: The mass ratio of cholesterol to lecithin is 1:4.

Citation Information

Patent Citations

  • Nanometer traditional Chinese medicine lipidosome hydrogel preparation for treating bone and joint diseases as well as preparation method thereof

    CN108837056A

  • Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof

    CN114796438A

  • Liposome containing active components

    CN117838636A